Kura Oncology Stock Buy Hold or Sell Recommendation


USD 14.98  0.28  1.90%   

Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Kura Oncology is 'Hold'. Macroaxis provides Kura Oncology buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding KURA positions. The advice algorithm takes into account all of Kura Oncology's available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from Kura Oncology's buy-and-hold perspective. Please see Kura Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Kura Oncology and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Kura Oncology.

Execute Kura Oncology Buy or Sell Advice

The Kura Oncology recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Kura Oncology. Macroaxis does not own or have any residual interests in Kura Oncology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Kura Oncology's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Kura OncologyBuy Kura Oncology



Hype Condition


Current Valuation


Odds of Distress


Economic Sensitivity


Analyst Consensus


Financial Strenth (F Score)


Financial Leverage


Reporting Quality (M-Score)

For the selected time horizon Kura Oncology has a Risk Adjusted Performance of 0.0179, Jensen Alpha of (0.003505), Total Risk Alpha of (0.046196), Sortino Ratio of (0.00111) and Treynor Ratio of 0.0216
Our investment recommendation tool can cross-verify current analyst consensus on Kura Oncology and to analyze the entity potential to grow in the current economic cycle. To make sure Kura Oncology is not overpriced, please verify all Kura Oncology fundamentals, including its cash and equivalents, earnings per share, current asset, as well as the relationship between the current ratio and market capitalization . Given that Kura Oncology has a price to earning of (9.03) X, we recommend you to check Kura Oncology market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

Kura Oncology Trading Alerts and Improvement Suggestions

Kura Oncology has very high historical volatility over the last 90 days
Kura Oncology is unlikely to experience financial distress in the next 2 years
Net Loss for the year was (133.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Kura Oncology currently holds about 450.26 M in cash with (110.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73.
Kura Oncology has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Is Kura Oncology Stock Outpacing Its Medical Peers This Year - Nasdaq

Kura Oncology current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kura Oncology analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kura Oncology analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Mean Price32.67
Target Median Price31.00
Target High Price47.00
Recommendation Mean1.70
Number Of Analyst Opinions9
Target Low Price22.00
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

Kura Oncology Returns Distribution Density

The distribution of Kura Oncology's historical returns is an attempt to chart the uncertainty of Kura Oncology's future price movements. The chart of the probability distribution of Kura Oncology stock daily returns describes the distribution of returns around its average expected value. We use Kura Oncology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Kura Oncology returns is essential to provide solid investment advice for Kura Oncology.
Mean Return0.0313Value At Risk-5.68
Potential Upside5.83Standard Deviation3.82
   Return Density   
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Kura Oncology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Kura Oncology Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kura Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kura Oncology backward and forwards among themselves. Kura Oncology's institutional investor refers to the entity that pools money to purchase Kura Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K127 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K112 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K97 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K130 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K145 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K196 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares6.9 K227 K
Note, although Kura Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kura Oncology Cash Flow Accounts

201720182019202020212022 (projected)
Depreciation Amortization and Accretion31 K30 K10 K194 K558 K602.05 K
Net Cash Flow or Change in Cash and Cash Equivalents1.71 M4.69 M10.02 M299.57 M(234.82 M)(241 M)
Issuance Repayment of Debt Securities7.45 M(344 K)(623 K)(250 K)(7.86 M)(8.07 M)
Net Cash Flow from Financing53.57 M132.64 M111.1 M469.33 M(3.44 M)(3.53 M)
Net Cash Flow from Investing(23.42 M)(79.3 M)(46.33 M)(99.94 M)(126.83 M)(136.85 M)
Net Cash Flow Investment Acquisitions and Disposals(23.42 M)(79.3 M)(46.33 M)(97.77 M)(125.69 M)(129 M)
Net Cash Flow from Operations(28.44 M)(48.66 M)(54.76 M)(69.83 M)(104.55 M)(107.3 M)
Share Based Compensation4.54 M8.65 M9.41 M12.81 M23.58 M25.44 M

Kura Oncology Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Kura Oncology or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Kura Oncology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Kura Oncology stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW0.99
Overall volatility
Information ratio -0.001

Kura Oncology Volatility Alert

Kura Oncology shows above-average downside volatility for the selected time horizon. We advise investors to inspect Kura Oncology further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Kura Oncology future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Kura Oncology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Kura Oncology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Kura Oncology Fundamentals Vs Peers

Comparing Kura Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Kura Oncology's direct or indirect competition across all of the common fundamentals between Kura Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Kura Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Kura Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare Kura Oncology to competition
FundamentalsKura OncologyPeer Average
Return On Equity(26.45) %(0.31) %
Return On Asset(15.95) %(0.14) %
Current Valuation617.23 M16.62 B
Shares Outstanding66.56 M571.82 M
Shares Owned by Insiders2.77 %10.09 %
Shares Owned by Institutions108.98 %39.21 %
Number of Shares Shorted7.2 M4.71 M
Price to Earning(9.03) X28.72 X
Price to Book1.61 X9.51 X
EBITDA(134.14 M)3.9 B
Net Income(133.33 M)570.98 M
Cash and Equivalents450.26 M2.7 B
Cash per Share6.73 X5.01 X
Total Debt5.89 M5.32 B
Debt to Equity0.013 %48.70 %
Current Ratio25.73 X2.16 X
Book Value Per Share9.23 X1.93 K
Cash Flow from Operations(110.48 M)971.22 M
Short Ratio6.56 X4.00 X
Earnings Per Share(1.69) X3.12 X
Price to Earnings To Growth(0.35) X4.89 X
Number of Employees12318.84 K
Market Capitalization989.02 M19.03 B
Total Asset87.26 M29.47 B
Retained Earnings(218.48 M)9.33 B
Working Capital81.81 M1.48 B
Current Asset86.87 M9.34 B
Current Liabilities5.05 M7.9 B
Z Score94.18.72
   Acquisition by Parks Diane L of 23000 shares of Kura Oncology subject to Rule 16b-3 [view details]

Kura Oncology Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Kura Oncology . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Kura Oncology Buy or Sell Advice

When is the right time to buy or sell Kura Oncology? Buying financial instruments such as Kura Oncology Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
 2019 2020 2021 2022 (projected)
Current Assets239.6 M637.29 M522.29 M563.52 M
Total Assets241.97 M647.21 M534.05 M576.21 M

Use Investing Ideas to Build Portfolios

In addition to having Kura Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Growth Thematic Idea Now

Small Growth
Small Growth Theme
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Theme or any other thematic opportunities.
View All  Next Launch
Please see Kura Oncology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for analysis

When running Kura Oncology price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
998.8 M
Return On Assets
Return On Equity
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine Kura Oncology value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.